A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in patients
with various solid tumors and with deleterious mutations in Homologous Recombination Repair
(HRR) genes.